Antimicrobialpeptide 6b

Antimicrobialpeptide 6b (0.7-100 μg/mL; 20-24 h) exhibits an MIC of 1.5-6.2 μg/mL against drug-resistant Gram-positive bacteria (including MRSA and VRE), an MIC of 4-25 μg/mL against Gram-negative bacteria (including daptomycin-insensitive strains), and an MIC of 3.1-12.5 μg/mL against pathogenic fungi (A. fumigatus, Candida spp., 48-72 h)^[1].
Antimicrobialpeptide 6b (1-4×MIC; 0-24 h) exhibits rapid bactericidal activity against MRSA and E. coli; it can eradicate preformed bacterial (MRSA, E. coli) and fungal (A. fumigatus, C. albicans) biofilms^[1].
Antimicrobialpeptide 6b exerts its effects through a membrane-lytic mechanism, which induces increased PI uptake by microbial cell membranes and extracellular ATP leakage. SEM shows cell membrane damage and content effusion; the calcein leakage assay confirms its membrane-lytic activity^[1].
Antimicrobialpeptide 6b (1-100 μg/mL; 2 h) exhibits low hemolytic activity against human red blood cells, with an HC₅₀ of 610.82 μg/mL and a therapeutic index of approximately 407^[1].
Antimicrobialpeptide 6b (1-100 μg/mL; 24 h) exhibits IC₅₀ values of 472.3 and 431.3 μg/mL against human embryonic kidney cells (HEK-293) and human hepatocytes (HepaRG), respectively, with cell viability >90% even at high concentrations^[1].
Antimicrobialpeptide 6b (100 μM; 0-24 h) exhibits moderate in vitro plasma stability, with 16.90% remaining undegraded after incubation in human plasma for 24 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.